文献速递白血病造血干细胞移植与细胞治疗

靶向急性髓系白血病RUNX1移码突变的新抗原T细胞受体

A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2025-12-12

研究探索能否用免疫疗法靶向急性髓系白血病中RUNX1移码突变产生的替代阅读框蛋白。研究者将RUNX1移码突变构建体导入常见HLA I类等位基因的B细胞系,经免疫肽组学鉴定出13个新肽。用肽-MHC四聚体在健康人中筛选出针对4个HLA等位基因的5个新抗原的CD8 T细胞克隆,其中2个新抗原在携带内源性RUNX1移码突变的HLA-B*07:02阳性AML细胞系上被识别。其中一个TCR在体外和免疫缺陷小鼠中有效杀伤RUNX1突变AML细胞,TCR工程T细胞也杀伤患者来源AML细胞包括白血病干细胞。结论示RUNX1移码突变可被有效靶向,TCR免疫疗法对RUNX1突变AML有潜在价值。

要点

  • RUNX1移码突变产生替代阅读框新抗原,可作为免疫治疗靶点。
  • 鉴定出13个新肽,筛选出针对4个HLA等位基因5个新抗原的T细胞克隆。
  • 一个TCR可杀伤RUNX1突变AML细胞及患者白血病干细胞。

核心结论

  • RUNX1移码突变可被TCR工程T细胞有效靶向,提示TCR免疫疗法对RUNX1突变AML有潜在相关性。

研究设计与样本

  • 将携带RUNX1移码突变的构建体导入具有常见HLA I类等位基因的B细胞系,用免疫肽组学鉴定新肽。
  • 用肽-MHC四聚体在健康个体中筛选RUNX1新抗原特异性CD8 T细胞,分离T细胞克隆并测序TCR。
  • 将TCR转移至CD8 T细胞后,在体外和免疫缺陷小鼠中评估对RUNX1突变AML细胞及患者来源AML细胞的杀伤。

主要发现

  • 免疫肽组学鉴定出13个新肽。
  • 针对4个HLA等位基因的5个新抗原分离出T细胞克隆。
  • 2个新抗原在HLA-B*07:02阳性且携带内源性RUNX1移码突变的AML细胞系上被识别。
  • 一个TCR在体外和免疫缺陷小鼠中诱导对RUNX1突变AML细胞的有效杀伤。
  • TCR工程T细胞也杀伤患者来源AML细胞,包括白血病干细胞。

临床怎么用

  • 对携带RUNX1移码突变的AML患者,TCR工程T细胞可能成为靶向新抗原的免疫治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Runt-related transcription factor 1 (RUNX1) is a key regulator of hematopoietic differentiation. RUNX1 mutations in acute myeloid leukemia (AML) are associated with poor prognosis. One-third are frameshift mutations encoding an oncogenic protein with an elongated C-terminus translated in an alternative reading frame. Here, we investigated whether the alternative reading frame of oncogenic RUNX1 can be targeted by immunotherapy. We introduced a construct with a RUNX1 frameshift mutation into B-cell lines with common HLA class I alleles and identified 13 neopeptides by immunopeptidomics. To investigate whether these peptides are neoantigens, peptide-MHC tetramers were used to screen healthy individuals for RUNX1 neoantigen-specific CD8 T cells. T-cell clones were isolated against 5 neoantigens in 4 HLA alleles. Two neoantigens were recognized on an HLA-B*07:02-positive AML cell line with an endogenous RUNX1 frameshift mutation. The T-cell receptors (TCRs) of these clones were sequenced, and analyzed after transfer into CD8 T cells. One TCR induced effective killing of RUNX1-mutated AML cells in vitro and in immunodeficient mice. TCR-engineered T cells also killed patient-derived AML cells, including leukemic stem cells. In conclusion, we showed that RUNX1 frameshift mutations can be effectively targeted, demonstrating the potential relevance of TCR-based immunotherapy to treat patients with RUNX1-mutated AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Struckman NE, Koutsoumpli G, de Jong RCM, et al. A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia. Leukemia. 2025. PMID: 41388195. doi:10.1038/s41375-025-02817-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。